Compare EQIX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQIX | BMY |
|---|---|---|
| Founded | 1998 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1B | 127.0B |
| IPO Year | 2000 | 2006 |
| Metric | EQIX | BMY |
|---|---|---|
| Price | $971.99 | $59.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 35 | 28 |
| Target Price | ★ $1,234.88 | $65.25 |
| AVG Volume (30 Days) | 610.3K | ★ 9.0M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | 2.03% | ★ 4.32% |
| EPS Growth | 61.88 | ★ 178.46 |
| EPS | ★ 13.96 | 3.98 |
| Revenue | $5,998,545,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $11.77 | $4.23 |
| Revenue Next Year | $11.35 | N/A |
| P/E Ratio | $72.93 | ★ $14.66 |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $720.62 | $47.58 |
| 52 Week High | $1,128.68 | $68.64 |
| Indicator | EQIX | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 39.40 |
| Support Level | $930.35 | $55.66 |
| Resistance Level | $984.17 | $60.93 |
| Average True Range (ATR) | 33.74 | 1.71 |
| MACD | -4.65 | -0.46 |
| Stochastic Oscillator | 3.38 | 13.93 |
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.